Market News AIOpen the app

Novo Nordisk says its new obesity drug helps people eat less and lose weight.

TrialRead the original at Benzinga
Good for NVO

Novo Nordisk reported weight loss across CagriSema studies and among people using the Wegovy pill, supporting its obesity-drug business. CagriSema is still under review, so those study results have not yet become sales.

NVO · Novo Nordisk A/S

AI read · Good for NVO

The AI's read

The results give Novo more evidence that its obesity medicines can help people lose weight and manage cravings. Multiple CagriSema studies and people using the Wegovy pill reported weight loss. CagriSema is still under review, so its study results have not yet become sales.

Get alerts for NVO

Follow Novo Nordisk A/S (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVO
Free on the App Store and Google Play, or on the web.